Top

Published in:

01-05-2008

Is Laparoscopic Resection Adequate in Patients with Neuroendocrine Pancreatic Tumors?

Authors: Laureano Fernández-Cruz, Laia Blanco, Rebeca Cosa, Héctor Rendón

Published in: World Journal of Surgery | Issue 5/2008

Abstract

Since the first reports with laparoscopic resection of islet cell tumors in 1996, the experience worldwide is still limited, with only short-term outcomes available. Some have suggested that a malignant tumor is a contraindication to laparoscopic resection.

Aim The aim of this study was to evaluate the feasibility, safety, and long-term outcome of the laparoscopic approach in patients with functioning, nonfunctioning, or overt malignant pancreatic neuroendocrine tumor (PNT). To our knowledge this is the largest single-institution series on this subject to date.

Patients and methods A total of 49 consecutive patients (43 women, 6 men; mean age 58 years, range 22–83 years) underwent laparoscopic pancreatic surgery (LPS) from April 1998 to June 2007. Preoperative localization was done by computed tomography, magnetic resonance imaging, endoscopic ultrasonography, and Octreoscan imaging. Other than 9 PNTs localized in the head of the pancreas, all tumors were located in the left pancreas. Malignancy was diagnosed based on the presence of lymph nodes or liver metastasis. There were 33 patients with functioning tumors: 4 with gastrinomas (mean size 1.2 cm), 1 with a glucagonoma (4 cm), 3 with vipomas (3.2 cm), 2 with carcinoids (5.2 cm), 20 with sporadic insulinomas (1.4 cm), 2 with insulinoma/multiple endocrine neoplasia type 1 (MEN-1) (4.4 cm), and 1 with a malignant insulinoma (13 cm). Sixteen patients had a nonfunctioning tumor (mean size 5 cm). The following techniques were performed: laparoscopic spleen-preserving distal pancreatectomy (Lap SPDP), laparoscopic distal pancreatectomy with splenectomy (Lap SxDP) and laparoscopic enucleation (Lap En)/laparoscopic excision (Lap E). Lymph node dissection was performed when malignancy was suspected (Strasberg´s technique). Evaluation criteria included operative and postoperative factors, pathologic data including R0 or R1 resection (the pancreatic transection margin and all transection margins on the specimen were inked). Long-term outcomes were analyzed by tumor recurrence and patient survival.

Results Four cases (8.2%) were converted to open surgery. Overall, Lap SPDP, Lap SxDP, and Lap En/Lap E were performed in 15 (33.3%), 8 (17.8%), and 22 (48.9%) patients, respectively. The operative time and blood loss was significantly lower in the Lap En group compared with the other laparoscopic techniques. The group of patients with malignant tumors undergoing Lap SxDP had a longer operating time and greater blood loss compared with the other distal pancreatectomy (Lap DP) techniques. Overall, the postoperative complications were significantly higher in the Lap En group (42.8%) than in the Lap DP (Lap SPDP + Lap SxDP) group (22%). These complications were mainly pancreatic fistula: 8.7% after Lap DP and 38% after Lap En. The overall morbidity was significantly higher after Lap SPDP (26.7%) than after Lap SxDP (12.5%) owing to the occurrence of splenic complications in the Lap SPDP group without splenic vessel preservation two of seven (28.5%). The means and ranges of hospital stay after Lap SPDP, Lap SxDP, and Lap En/Lap E were 5.9 (5–14), 7.5 (5–12), and 5.5 (5–7) days, respectively (NS). Pathology examination of the specimen showed R0 resection in all patients with malignant PNT. The mean time to resumption of previous activities for patients undergoing Lap DP or Lap En was 3 weeks. There were no postoperative (30 days) or hospital deaths.

Conclusions This series demonstrates that LPS is feasible and safe in benign-appearing and malignant neuroendocrine pancreatic tumors (NEPTs). The benefits of minimally invasive surgery were manifest in the short hospital stay and acceptable pancreas-related complications in high-risk patients. LPS can achieve negative tangential margins in a high percentage of patients with malignant tumors. Although surgical cure is rare in malignant NEPTs, significant long-term palliation can be achieved in a large proportion of patients with an aggressive surgical approach.

Stephen AE, Hodin RA (2006) Neuroendocrine tumors of the pancreas, excluding gastrinoma. Surg Oncol Clin N Am 15:497–510PubMedCrossRef

Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776–785PubMedCrossRef

Sarmiento JM, Que FG, Grant CS et al (2002) Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 132:976–982PubMedCrossRef

Bartsch DK, Langer P, Wild A et al (2000) Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery and surveillance. Surgery 128:958–966PubMedCrossRef

Demeure M, Klonoff D, Karam J et al (1991) Insulinomas associated with multiple endocrine neoplasia type 1: the needs for a different surgical approach. Surgery 110:998–1005PubMed

Cadiot G, Vuagnat A, Doukhan I et al (1999) Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Gastroenterology 116:286–293PubMedCrossRef

Gagner M, Pomp A (1994) Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc 8:408–410PubMedCrossRef

Cushieri A (1994) Laparoscopic surgery of the pancreas. J R Coll Surg Edinb 39:187–194

Gagner M, Pomp A, Herrera MF (1996) Early experience with laparoscopic resection of islet cell tumors. Surgery 120:1051–1054PubMedCrossRef

10.

Assalia A, Gagner M (2004) Laparoscopic pancreatic surgery for islet cell tumors of the pancreas. World J Surg 28:1239–1247PubMedCrossRef

11.

Mabrut JY, Fernández-Cruz L, Azagra JS et al (2005) Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 137:597–605PubMedCrossRef

12.

Patterson EJ, Gagner M, Salky B et al (2001) Laparoscopic pancreatic resection: single-institution experience with 19 patients. J Am Coll Surg 193:281–287PubMedCrossRef

13.

Kloppel G, Perren A, Hertz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 1014:13–27PubMedCrossRef

14.

Kimura W, Inone T, Futawake N et al (1996) Spleen preserving distal pancreatectomy with conservation of the splenic artery and vein. Surgery 120:885–890PubMedCrossRef

15.

Warshaw L (1998) Conservation of the spleen with distal pancreatectomy. Arch Surg 123:550–553

16.

Fernández-Cruz L, Martinez I, Gilabert R et al (2004) Laparoscopic distal pancreatectomy combined with preservation of the spleen for cystic neoplasms of the pancreas. J Gastrointest Surg 8:493–501PubMedCrossRef

17.

Fernández-Cruz L (2006) Distal pancreatic resection: technical differences between open and laparoscopic approaches. HPB 8:49–56PubMed

18.

Strasberg SM, Drebin JA, Linehan D (2003) Radical antegrade modular pancreatosplenectomy. Surgery 133:521–527PubMedCrossRef

19.

Fernández-Cruz L, Cosa R, Blanco L et al (2007) Curative laparoscopic resection for pancreatic neoplasms: A critical analisis from a single institution. J Gastrointest Surg 11:1607–1622PubMedCrossRef

20.

Fernández-Cruz L, Martinez I, Cesar-Borges G et al (2005) Laparoscopic surgery in patients with sporadic and multiple insulinomas associated with multiple endocrine neoplasia type 1. J Gastrointest Surg 9:381–388PubMedCrossRef

21.

Fernández-Cruz L, César-Borges G (2006) Laparoscopic strategies for resection of insulinoma. J Gastrointest Surg 10:752–760PubMedCrossRef

22.

Fernández-Cruz L, Sáenz A, Astudillo E et al (2002) Outcome of laparoscopic pancreatic surgery: endocrine and nonendocrine tumors. World J Surg 26:1057–1065PubMedCrossRef

23.

Bassi C, Dervenis C, Butturini G et al (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8–13PubMedCrossRef

24.

Bartsch DK, Schilling T, Ramaswamy A et al (2000) Management of nonfunctioning islet cell carcinomas. World J Surg 24:1418–1424PubMedCrossRef

25.

Kouvaraki MA, Solorzano CC, Saphiro SE et al (2005) Surgical treatment of non-functioning pancreatic islet cell tumors. J Surg Oncol 89:170–185PubMedCrossRef

26.

Kazanjiam KK, Reber HA, Hines OJ (2006) Resection of pancreatic neuroendocrine tumors. Arch Surg 141:765–770CrossRef

27.

Salorzano CC, Lee JE, Pisters PW et al (2001) Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130:1078–1085CrossRef

28.

Phan GQ, Yeo CJ, Hruban RH et al (1998) Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J. Gastrointest Surg 2:472–482PubMedCrossRef

29.

House MG, Cameron JL, Lillemoe KD et al (2006) Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 10:138–145PubMedCrossRef

30.

Schurr PG, Strate T, Rese K et al (2007) Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 245:273–281PubMedCrossRef

31.

Fendrich V, Langer P, Celiki I et al (2006) An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 244:845–853PubMedCrossRef

32.

Dralle H, Krohn SL, Karges W et al (2004) Surgery of resectable non-functioning neuroendocrine pancreatic tumors. World J Surg 28:1248–1260PubMedCrossRef

33.

Chung JC, Choi DW, Jo SH et al (2007) Malignant non-functioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment. World J Surg 31:579–585PubMedCrossRef

34.

Libutti SK, Alexander HR Jr (2006) Gastrinoma: sporadic and familial disease. Surg Oncol Clin N Am 15:479–496PubMedCrossRef

35.

Kisker O, Bastian D, Bartsch D et al (1998) Localization, malignant potential and surgical management of gastrinomas. World J Surg 22:651–658PubMedCrossRef

36.

Roy PK, Venzon DJ, Shojamanesh H et al (2000) Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore) 79:379–411CrossRef

37.

Norton JA, Fraker DL, Alexander HR et al (1999) Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341:635–644PubMedCrossRef

38.

Norton JA, Jensen RT (2004) Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 240:757–773PubMedCrossRef

39.

Norton JA, Alexander HR, Fraker DL et al (2003) Possibly primary lymph node gastrinomas: occurrence, natural history and predictive factors; a prospective study. Ann Surg 237:650–659PubMedCrossRef

40.

Smith SL, Branton SA, Avino AJ et al (1998) Vasoactive intestinal polypeptide secreting islet cell tumors; a 15-year experience and review of the literature. Surgery 124:1050–1055PubMedCrossRef

41.

Olausson M, Friman S, Herlenius G et al (2007) Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 13:327–333PubMedCrossRef

42.

Florman S, Toure B, Kim L et al (2004) Liver transplantation for neuroendocrine tumor. J Gastrointest Surg 8:208–212PubMedCrossRef

43.

Wermers RA, Fatonrechi V, Wynne AG et al (1996) The glucagonoma syndrome: clinical and pathological features in 21 patients. Medicine 75:53–63PubMedCrossRef

44.

Weinel RJ, Neuhaus C, Stapp J et al (1993) Preoperative localization of gastrointestinal endocrine tumors using somatostatin-receptor scintigraphy. Ann Surg 218:640–645PubMedCrossRef

45.

Kirshbom PM, Kherai AR, Onaitis MW et al (1999) Foregut carcinoids: a clinical and biochemical analysis. Surgery 126:1105–1110PubMedCrossRef

46.

Maurer CA, Baer H-U, Dyong TH et al (1996) Carcinoid of the pancreas: clinical characteristics and morphological features. Eur J Cancer 32:1109–1116CrossRef

47.

Norton JA (1994) Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 55(Suppl 3):98–103PubMedCrossRef

48.

Norton JA, Well SA Jr (1994) The surgical management of patients with multiple endocrine neoplasia type I. World J Surg 18:488–494CrossRef

49.

O’Riordan D, O’Brien M, van Heerden JA et al (1994) Surgical management of insulinomas associated with múltiple endocrine neoplasia type I. World J Surg 8:488–494CrossRef

50.

Thompson NW (1998) Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surg Oncol Clin N Am 7:881–891PubMed

51.

Doherty GM, Thompson NW (2003) Multiple endocrine neoplasia type 1: duodenopancreatic tumors. J Intern Med 253:590–598PubMedCrossRef

52.

Skogseid B, Eviksson B, Lundquist G et al (1991) Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 73:281–289PubMedCrossRef

53.

Äkerstrom G, Hessman O, Skogreid B (2002) Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN-1. Langenbecks Arch Surg 386:558–569PubMedCrossRef

54.

Bartsch DK, Fendrich V, Langer P et al (2005) Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type-1. Ann Surg 242:757–766PubMedCrossRef

55.

Äkerstrom G, Hellman P, Skogseid B (2005) Pancreatic tumors as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol 19:819–830PubMedCrossRef

56.

Zogakis TG, Gibril F, Libutti SK et al (2003) Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg 238:42–48PubMedCrossRef

57.

Jensen RT (1998) Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 243:477–488PubMedCrossRef

58.

Danforth DN Jr, Gorden P, Brennan MF (1984) Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 96:1027–1037PubMed

59.

Starke A, Saddig C, Manfeld L et al (2005) Malignant metastatic insulinoma: postoperative treatment and follow-up. World J Surg 29:789–793PubMedCrossRef

60.

Hirshberg B, Cochran C, Skarulis M et al (2005) Malignant insulinoma. Cancer 104:264–272PubMedCrossRef

61.

Tucker ON, Crotty PL, Conlon KC (2006) The management of insulinoma. Br J Surg 93:264–265PubMedCrossRef

62.

Thoeni RF, Mueller-Lisse UG, Chan R et al (2000) Detection of small functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 212:483–490

63.

Grant CS (1998) Insulinoma. Surg Oncol Clin N Am 7:819–844PubMed

64.

Berends FJ, Cuesta MA, Kazemier G et al (2000) Laparoscopic detection and resection of insulinomas. Surgery 128:386–390PubMedCrossRef

65.

Gramatica L, Herrera MF, Mercado-Luna A et al (2002) Video-laparoscopic resection of insulinomas. World J Surg 26:1297–1300PubMedCrossRef

66.

Ihiara M, Obara T (2002) Minimally invasive endocrine surgery: laparoscopic resection of insulinomas. Biomed Pharmacother 56:227–230CrossRef

67.

Ayav A, Bresler L, Brunand L et al (2005) Laparoscopic approach for insulinoma: a multicenter study. Langenbecks Arch Surg 390:134–140PubMedCrossRef

68.

Toniato A, Meduri F, Foletts M et al (2006) Laparoscopic treatment of benign insulinomas localized in the body and tail of the pancreas. World J Surg 30:1916–1919PubMedCrossRef

69.

Jaroszewski D, Schlinkert RT, Thompson GB et al (2004) Laparoscopic localization and resection of insulinomas. Arch Surg 139:270–274PubMedCrossRef

70.

Sa Cunha A, Beau C, Rault A et al (2007) Laparoscopic versus open approach for solitary insulinoma. Surg Endosc 21:103–108PubMedCrossRef

71.

Lo CY, Lo CM, Fan SM (2000) Role of laparoscopic ultrasonography in intraoperative localization of pancreatic insulionoma. Surg Endosc 14:1131–1135PubMedCrossRef

72.

Rothmund M, Angelini L, Brunt LM et al (1990) Surgery for benign insulinoma: an international review. World J Surg 14:393–398PubMedCrossRef

73.

Hellman P, Goretzki P, Simon D et al (2000) Therapeutic experience of 65 cases with organic hyperinsulinism. Langenbecks Arch Surg 385:329–336PubMedCrossRef

74.

Park BJ, Alexander HR, Libatti SK et al (1998) Operative management of islet cell tumor arising in the head of the pancreas. Surgery 124:1056–1061PubMedCrossRef

75.

Knaebel HP, Diener MK, Wente MN et al (2005) Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br J Surg 92:539–546PubMedCrossRef

76.

Velanovich V (2006) Case-control comparison of laparoscopic versus open distal pancreatectomy. J Gastrointest Surg 10:95–98PubMedCrossRef

Title: Is Laparoscopic Resection Adequate in Patients with Neuroendocrine Pancreatic Tumors?
Authors: Laureano Fernández-Cruz
Laia Blanco
Rebeca Cosa
Héctor Rendón
Publication date: 01-05-2008
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 5/2008
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-008-9467-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is Laparoscopic Resection Adequate in Patients with Neuroendocrine Pancreatic Tumors?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Age- and Sex-Related Incidence of Surgically Treated Primary Hyperparathyroidism

Tumor Size Predicts Malignant Potential in Hürthle Cell Neoplasms of the Thyroid

Long-term Outcome of Reoperations for Medullary Thyroid Carcinoma

Safety of Laparoscopic Adrenalectomy in Patients with Large Pheochromocytomas: A Single Institution Review

Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors

The Value of Positron Emission Tomography in the Surgical Management of Recurrent Papillary Thyroid Carcinoma